{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T14:54:53Z","timestamp":1762008893959,"version":"build-2065373602"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T00:00:00Z","timestamp":1545091200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 81301118"],"award-info":[{"award-number":["No. 81301118"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s10072-018-3681-y","type":"journal-article","created":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T01:01:28Z","timestamp":1545094888000},"page":"523-528","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Lack of association between valproic acid response and polymorphisms of its metabolism, transport, and receptor genes in children with focal seizures"],"prefix":"10.1007","volume":"40","author":[{"given":"Weixing","family":"Feng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shenghui","family":"Mei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaqi","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leting","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yazhen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baoqin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiuwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0281-2259","authenticated-orcid":false,"given":"Zhigang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,12,18]]},"reference":[{"issue":"2","key":"3681_CR1","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/S1474-4422(15)00314-2","volume":"15","author":"T Tomson","year":"2016","unstructured":"Tomson T, Battino D, Perucca E (2016) Valproic acid after five decades of use in epilepsy: time to reconsider the indications of a time-honoured drug. Lancet Neurol 15(2):210\u2013218","journal-title":"Lancet Neurol"},{"issue":"3","key":"3681_CR2","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s10072-017-3232-y","volume":"39","author":"M Dedei Daryan","year":"2018","unstructured":"Dedei Daryan M, Guveli BT, Baslo SA, Mulhan K, Sari H, Balcik ZE, Atakli D (2018) Prevalence and clinical characteristics of headache in juvenile myoclonic epilepsy: experience from a tertiary epilepsy center. Neurol Sci 39(3):519\u2013525","journal-title":"Neurol Sci"},{"issue":"2","key":"3681_CR3","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s00210-010-0531-8","volume":"382","author":"OK Steinlein","year":"2010","unstructured":"Steinlein OK (2010) Gene polymorphisms and their role in epilepsy treatment and prognosis. Naunyn Schmiedeberg's Arch Pharmacol 382(2):109\u2013118","journal-title":"Naunyn Schmiedeberg's Arch Pharmacol"},{"issue":"4","key":"3681_CR4","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1097\/FPC.0b013e32835ea0b2","volume":"23","author":"Y Ghodke-Puranik","year":"2013","unstructured":"Ghodke-Puranik Y, Thorn CF, Lamba JK, Leeder JS, Song W, Birnbaum AK, Altman RB, Klein TE (2013) Valproic acid pathway: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics 23(4):236\u2013241","journal-title":"Pharmacogenet Genomics"},{"issue":"6","key":"3681_CR5","doi-asserted-by":"publisher","first-page":"439","DOI":"10.2165\/00003088-199936060-00005","volume":"36","author":"SN Wildt de","year":"1999","unstructured":"de Wildt SN, Kearns GL, Leeder JS, van den Anker JN (1999) Glucuronidation in humans. Pharmacogenetic and developmental aspects. Clin Pharmacokinet 36(6):439\u2013452","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"3681_CR6","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1111\/epi.13011","volume":"56","author":"T Budi","year":"2015","unstructured":"Budi T, Toth K, Nagy A, Szever Z, Kiss A, Temesvari M, Hafra E, Garami M, Tapodi A, Monostory K (2015) Clinical significance of CYP2C9-status guided valproic acid therapy in children. Epilepsia 56(6):849\u2013855","journal-title":"Epilepsia"},{"issue":"8","key":"3681_CR7","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.2217\/pgs.11.64","volume":"12","author":"CC Hung","year":"2011","unstructured":"Hung CC, Ho JL, Chang WL, Tai JJ, Hsieh TJ, Hsieh YW, Liou HH (2011) Association of genetic variants in six candidate genes with valproic acid therapy optimization. Pharmacogenomics 12(8):1107\u20131117","journal-title":"Pharmacogenomics"},{"issue":"5","key":"3681_CR8","doi-asserted-by":"publisher","first-page":"536","DOI":"10.2133\/dmpk.DMPK-11-NT-144","volume":"27","author":"Y Guo","year":"2012","unstructured":"Guo Y, Hu C, He X, Qiu F, Zhao L (2012) Effects of UGT1A6, UGT2B7, and CYP2C9 genotypes on plasma concentrations of valproic acid in Chinese children with epilepsy. Drug Metab Pharmacokinet 27(5):536\u2013542","journal-title":"Drug Metab Pharmacokinet"},{"issue":"8","key":"3681_CR9","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s00228-018-2440-6","volume":"74","author":"S Mei","year":"2018","unstructured":"Mei S, Feng W, Zhu L, Li X, Yu Y, Yang W, Gao B, Wu X, Fang F, Zhao Z (2018) Effect of CYP2C19, UGT1A8, and UGT2B7 on valproic acid clearance in children with epilepsy: a population pharmacokinetic model. Eur J Clin Pharmacol 74(8):1029\u20131036","journal-title":"Eur J Clin Pharmacol"},{"key":"3681_CR10","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.seizure.2017.07.005","volume":"51","author":"S Mei","year":"2017","unstructured":"Mei S, Feng W, Zhu L, Yu Y, Yang W, Gao B, Wu X, Zhao Z, Fang F (2017) Genetic polymorphisms and valproic acid plasma concentration in children with epilepsy on valproic acid monotherapy. Seizure 51:22\u201326","journal-title":"Seizure"},{"issue":"6","key":"3681_CR11","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1097\/FTD.0000000000000337","volume":"38","author":"W Feng","year":"2016","unstructured":"Feng W, Mei S, Zhu L, Yu Y, Yang W, Gao B, Wu X, Zhao Z, Fang F (2016) Effects of UGT1A6 and GABRA1 on standardized valproic acid plasma concentrations and treatment effect in children with epilepsy in China. Ther Drug Monit 38(6):738\u2013743","journal-title":"Ther Drug Monit"},{"issue":"8","key":"3681_CR12","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1111\/j.1755-5949.2012.00336.x","volume":"18","author":"J Qu","year":"2012","unstructured":"Qu J, Zhou BT, Yin JY, Xu XJ, Zhao YC, Lei GH, Tang Q, Zhou HH, Liu ZQ (2012) ABCC2 polymorphisms and haplotype are associated with drug resistance in Chinese epileptic patients. CNS Neurosci Ther 18(8):647\u2013651","journal-title":"CNS Neurosci Ther"},{"issue":"15","key":"3681_CR13","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1056\/NEJMoa021986","volume":"348","author":"A Siddiqui","year":"2003","unstructured":"Siddiqui A, Kerb R, Weale ME, Brinkmann U, Smith A, Goldstein DB, Wood NW, Sisodiya SM (2003) Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med 348(15):1442\u20131448","journal-title":"N Engl J Med"},{"issue":"1","key":"3681_CR14","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12883-017-0801-x","volume":"17","author":"M Chouchi","year":"2017","unstructured":"Chouchi M, Kaabachi W, Klaa H, Tizaoui K, Turki IB, Hila L (2017) Relationship between ABCB1 3435TT genotype and antiepileptic drugs resistance in epilepsy: updated systematic review and meta-analysis. BMC Neurol 17(1):32","journal-title":"BMC Neurol"},{"key":"3681_CR15","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.jocn.2016.10.014","volume":"37","author":"L Qian","year":"2017","unstructured":"Qian L, Fang S, Yan YL, Zeng SS, Xu ZJ, Gong ZC (2017) The ABCC2 c.-24C>T polymorphism increases the risk of resistance to antiepileptic drugs: a meta-analysis. J Clin Neurosci 37:6\u201314","journal-title":"J Clin Neurosci"},{"issue":"7","key":"3681_CR16","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.seizure.2011.04.003","volume":"20","author":"BS Haerian","year":"2011","unstructured":"Haerian BS, Lim KS, Mohamed EH, Tan HJ, Tan CT, Raymond AA, Wong CP, Wong SW, Mohamed Z (2011) Lack of association of ABCB1 haplotypes on five loci with response to treatment in epilepsy. Seizure 20(7):546\u2013553","journal-title":"Seizure"},{"issue":"6","key":"3681_CR17","first-page":"416","volume":"70","author":"L Zhou","year":"2015","unstructured":"Zhou L, Cao Y, Long H, Long L, Xu L, Liu Z, Zhang Y, Xiao B (2015) ABCB1, ABCC2, SCN1A, SCN2A, GABRA1 gene polymorphisms and drug resistant epilepsy in the Chinese Han population. Pharmazie 70(6):416\u2013420","journal-title":"Pharmazie"},{"issue":"7","key":"3681_CR18","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/nrn1430","volume":"5","author":"MA Rogawski","year":"2004","unstructured":"Rogawski MA, Loscher W (2004) The neurobiology of antiepileptic drugs. Nat Rev Neurosci 5(7):553\u2013564","journal-title":"Nat Rev Neurosci"},{"issue":"4","key":"3681_CR19","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.seizure.2010.02.009","volume":"19","author":"R Kumari","year":"2010","unstructured":"Kumari R, Lakhan R, Kalita J, Misra UK, Mittal B (2010) Association of alpha subunit of GABAA receptor subtype gene polymorphisms with epilepsy susceptibility and drug resistance in north Indian population. Seizure 19(4):237\u2013241","journal-title":"Seizure"},{"issue":"8","key":"3681_CR20","doi-asserted-by":"publisher","first-page":"5457","DOI":"10.1007\/s12035-015-9457-y","volume":"53","author":"BS Haerian","year":"2016","unstructured":"Haerian BS, Baum L, Kwan P, Cherny SS, Shin JG, Kim SE, Han BG, Tan HJ, Raymond AA, Tan CT, Mohamed Z (2016) Contribution of GABRG2 polymorphisms to risk of epilepsy and febrile seizure: a multicenter cohort study and meta-analysis. Mol Neurobiol 53(8):5457\u20135467","journal-title":"Mol Neurobiol"},{"issue":"11","key":"3681_CR21","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1097\/FPC.0000000000000000","volume":"23","author":"S Balan","year":"2013","unstructured":"Balan S, Sathyan S, Radha SK, Joseph V, Radhakrishnan K, Banerjee M (2013) GABRG2, rs211037 is associated with epilepsy susceptibility, but not with antiepileptic drug resistance and febrile seizures. Pharmacogenet Genomics 23(11):605\u2013610","journal-title":"Pharmacogenet Genomics"},{"issue":"10","key":"3681_CR22","doi-asserted-by":"publisher","first-page":"669","DOI":"10.2165\/00023210-200216100-00003","volume":"16","author":"W Loscher","year":"2002","unstructured":"Loscher W (2002) Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs 16(10):669\u2013694","journal-title":"CNS Drugs"},{"issue":"1","key":"3681_CR23","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.gene.2013.09.071","volume":"533","author":"L Tang","year":"2014","unstructured":"Tang L, Lu X, Tao Y, Zheng J, Zhao P, Li K, Li L (2014) SCN1A rs3812718 polymorphism and susceptibility to epilepsy with febrile seizures: a meta-analysis. Gene 533(1):26\u201331","journal-title":"Gene"},{"issue":"18","key":"3681_CR24","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.2217\/pgs-2016-0093","volume":"17","author":"X Li","year":"2016","unstructured":"Li X, Zhang J, Wu X, Yan H, Zhang Y, He RH, Tang YJ, He YJ, Tan D, Mao XY, Yin JY, Liu ZQ, Zhou HH, Liu J (2016) Polymorphisms of ABAT, SCN2A and ALDH5A1 may affect valproic acid responses in the treatment of epilepsy in Chinese. Pharmacogenomics 17(18):2007\u20132014","journal-title":"Pharmacogenomics"},{"issue":"11","key":"3681_CR25","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1097\/FPC.0b013e3283117d67","volume":"18","author":"P Kwan","year":"2008","unstructured":"Kwan P, Poon WS, Ng HK, Kang DE, Wong V, Ng PW, Lui CH, Sin NC, Wong KS, Baum L (2008) Multidrug resistance in epilepsy and polymorphisms in the voltage-gated sodium channel genes SCN1A, SCN2A, and SCN3A: correlation among phenotype, genotype, and mRNA expression. Pharmacogenet Genomics 18(11):989\u2013998","journal-title":"Pharmacogenet Genomics"},{"issue":"10","key":"3681_CR26","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.2217\/pgs.13.104","volume":"14","author":"BS Haerian","year":"2013","unstructured":"Haerian BS, Baum L, Kwan P, Tan HJ, Raymond AA, Mohamed Z (2013) SCN1A, SCN2A and SCN3A gene polymorphisms and responsiveness to antiepileptic drugs: a multicenter cohort study and meta-analysis. Pharmacogenomics 14(10):1153\u20131166","journal-title":"Pharmacogenomics"},{"issue":"Suppl 2","key":"3681_CR27","first-page":"25","volume":"37","author":"CL DeVane","year":"2003","unstructured":"DeVane CL (2003) Pharmacokinetics, drug interactions, and tolerability of valproate. Psychopharmacol Bull 37(Suppl 2):25\u201342","journal-title":"Psychopharmacol Bull"},{"key":"3681_CR28","doi-asserted-by":"publisher","first-page":"4362","DOI":"10.1038\/srep04362","volume":"4","author":"A Marahatta","year":"2014","unstructured":"Marahatta A, Bhandary B, Jeong SK, Kim HR, Chae HJ (2014) Soybean greatly reduces valproic acid plasma concentrations: a food-drug interaction study. Sci Rep 4:4362","journal-title":"Sci Rep"},{"issue":"7","key":"3681_CR29","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1007\/s10072-012-1190-y","volume":"34","author":"R Golmohammadi","year":"2013","unstructured":"Golmohammadi R, Pejhan A, Azhdari-Zarmehri H, Mohammad-Zadeh M (2013) The role of ethanol on the anticonvulsant effect of valproic acid and cortical microvascular changes after epileptogenesis in mice. Neurol Sci 34(7):1125\u20131131","journal-title":"Neurol Sci"},{"key":"3681_CR30","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.seizure.2018.04.006","volume":"58","author":"W Feng","year":"2018","unstructured":"Feng W, Mei S, Zhu L, Yu Y, Yang W, Gao B, Wu X, Zhao Z, Fang F (2018) Effects of UGT2B7, SCN1A and CYP3A4 on the therapeutic response of sodium valproate treatment in children with generalized seizures. Seizure 58:96\u2013100","journal-title":"Seizure"},{"issue":"4","key":"3681_CR31","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/epi.12550","volume":"55","author":"RS Fisher","year":"2014","unstructured":"Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, Engel J Jr, Forsgren L, French JA, Glynn M, Hesdorffer DC, Lee BI, Mathern GW, Moshe SL, Perucca E, Scheffer IE, Tomson T, Watanabe M, Wiebe S (2014) ILAE official report: a practical clinical definition of epilepsy. Epilepsia 55(4):475\u2013482","journal-title":"Epilepsia"},{"issue":"4","key":"3681_CR32","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1111\/j.1528-1167.2010.02522.x","volume":"51","author":"AT Berg","year":"2010","unstructured":"Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, van Emde Boas W, Engel J, French J, Glauser TA, Mathern GW, Moshe SL, Nordli D, Plouin P, Scheffer IE (2010) Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE commission on classification and terminology, 2005-2009. Epilepsia 51(4):676\u2013685","journal-title":"Epilepsia"},{"issue":"1","key":"3681_CR33","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.yebeh.2011.02.015","volume":"21","author":"H Meng","year":"2011","unstructured":"Meng H, Guo G, Ren J, Zhou H, Ge Y, Guo Y (2011) Effects of ABCB1 polymorphisms on plasma carbamazepine concentrations and pharmacoresistance in Chinese patients with epilepsy. Epilepsy Behav 21(1):27\u201330","journal-title":"Epilepsy Behav"},{"key":"3681_CR34","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/978-1-4939-6442-0_5","volume":"1492","author":"JA Ellis","year":"2017","unstructured":"Ellis JA, Ong B (2017) The MassARRAY(R) system for targeted SNP genotyping. Methods Mol Biol 1492:77\u201394","journal-title":"Methods Mol Biol"},{"issue":"2","key":"3681_CR35","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nprot.2010.182","volume":"6","author":"GM Clarke","year":"2011","unstructured":"Clarke GM, Anderson CA, Pettersson FH, Cardon LR, Morris AP, Zondervan KT (2011) Basic statistical analysis in genetic case-control studies. Nat Protoc 6(2):121\u2013133","journal-title":"Nat Protoc"},{"issue":"15","key":"3681_CR36","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1056\/NEJMe030023","volume":"348","author":"TA Pedley","year":"2003","unstructured":"Pedley TA, Hirano M (2003) Is refractory epilepsy due to genetically determined resistance to antiepileptic drugs? N Engl J Med 348(15):1480\u20131482","journal-title":"N Engl J Med"},{"issue":"12","key":"3681_CR37","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1046\/j.1528-1157.2001.12301.x","volume":"42","author":"SM Dombrowski","year":"2001","unstructured":"Dombrowski SM, Desai SY, Marroni M, Cucullo L, Goodrich K, Bingaman W, Mayberg MR, Bengez L, Janigro D (2001) Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy. Epilepsia 42(12):1501\u20131506","journal-title":"Epilepsia"},{"issue":"11","key":"3681_CR38","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1046\/j.1528-1157.2002.156702.x","volume":"43","author":"P Kwan","year":"2002","unstructured":"Kwan P, Sills GJ, Butler E, Gant TW, Meldrum BS, Brodie MJ (2002) Regional expression of multidrug resistance genes in genetically epilepsy-prone rat brain after a single audiogenic seizure. Epilepsia 43(11):1318\u20131323","journal-title":"Epilepsia"},{"issue":"6","key":"3681_CR39","doi-asserted-by":"publisher","first-page":"585","DOI":"10.4103\/0028-3886.105191","volume":"60","author":"LL Gitai","year":"2012","unstructured":"Gitai LL, de Almeida DH, Born JP, Gameleira FT, de Andrade TG, Machado LC, Gitai DL (2012) Lack of association between rs211037 of the GABRG2 gene and juvenile myoclonic epilepsy in Brazilian population. Neurol India 60(6):585\u2013588","journal-title":"Neurol India"},{"issue":"2","key":"3681_CR40","doi-asserted-by":"publisher","first-page":"236","DOI":"10.4103\/0972-2327.182304","volume":"19","author":"AB Dixit","year":"2016","unstructured":"Dixit AB, Banerjee J, Ansari A, Tripathi M, Chandra SP (2016) Mutations in GABRG2 receptor gene are not a major factor in the pathogenesis of mesial temporal lobe epilepsy in Indian population. Ann Indian Acad Neurol 19(2):236\u2013241","journal-title":"Ann Indian Acad Neurol"},{"key":"3681_CR41","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1007\/s10072-018-3583-z","volume":"39","author":"V Rai","year":"2018","unstructured":"Rai V, Kumar P (2018) Methylenetetrahydrofolate reductase C677T polymorphism and susceptibility to epilepsy. Neurol Sci 39:2033\u20132041","journal-title":"Neurol Sci"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-018-3681-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10072-018-3681-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-018-3681-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,16]],"date-time":"2020-01-16T10:31:53Z","timestamp":1579170713000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10072-018-3681-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,18]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["3681"],"URL":"https:\/\/doi.org\/10.1007\/s10072-018-3681-y","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"type":"print","value":"1590-1874"},{"type":"electronic","value":"1590-3478"}],"subject":[],"published":{"date-parts":[[2018,12,18]]},"assertion":[{"value":"11 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}